Skip to main content
Reported segment mix · SEC DERA dimensional facts

10x Genomics, Inc. TXG revenue by segment, product and geography

In its fiscal year ending 2025-12-31, 10x Genomics, Inc. reported revenue across 9 products and services; the largest, Product And Service Revenue, was $597M (-2.3% against the prior period in the same filing).

Reported segment mix

figures as filed · share of the filed sum · change vs the prior period in the same filing
Fiscal year ending 2025-12-3110-K filed 2026-02-13prior period 2024-12-31 from the same filingView filing
By product or service
Revenue
  • Product And Service Revenue$597M
    share n/a
    -2.3% yoy
  • Consumables$507M
    share n/a
    +2.8% yoy
  • Single Cell Consumables$363M
    share n/a
    -2.4% yoy
  • Spatial Consumables$144M
    share n/a
    +18.9% yoy
  • Instruments$56.8M
    share n/a
    -38.8% yoy
  • Licensing And Royalty Revenue$46.1M
    share n/a
    +14272.3% yoy
  • Spatial Instruments$34.1M
    share n/a
    -40.7% yoy
  • Service$32.7M
    share n/a
    +34.6% yoy
  • +1 more member in the filing

member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.

By geography
Revenue
  • Americas$359M
    share n/a
    +3.2% yoy
  • United States$347M
    share n/a
    +3.6% yoy
  • EMEA$162M
    share n/a
    +1.2% yoy
  • Asia Pacific$122M
    share n/a
    +18.5% yoy
  • China$70.3M
    share n/a
    +22.6% yoy
  • Asia Pacific Excluding China$52.1M
    share n/a
    +13.3% yoy
  • Americas Excluding United States$12.3M
    share n/a
    -8.8% yoy

member sum exceeds the consolidated figure: this axis carries more than one breakdown, so shares are not computed.

Latest quarter
Quarter ending 2026-03-3110-Q filed 2026-05-08prior period 2025-03-31 from the same filingView filing
  • Product And Service Revenue$150M
    share n/a
    +8.8% yoy
  • Consumables$130M
    share n/a
    +12.5% yoy
  • Chromium Consumables$88.9M
    share n/a
    +5.7% yoy
  • Spatial Consumables$40.9M
    share n/a
    +30.9% yoy
  • Instruments$11.3M
    share n/a
    -24.0% yoy
  • Service$8.83M
    share n/a
    +15.4% yoy
  • +3 more members in the filing

Change is against the same quarter a year earlier, as reported in the same 10-Q.

Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.

About these figures

Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.

Descriptive and educational; not investment advice. Methodology and data lineage.

Educational content only. Not financial advice. TrendNalysis provides educational and informational financial analysis built from public SEC filings and economic data (FRED, BLS). It is not financial, investment, tax, or legal advice and is not a recommendation to buy or sell any security. Market pricing is not currently included. Past performance does not guarantee future results. Always do your own research and consult a licensed financial professional before investing.

10x Genomics, Inc. (TXG) revenue by segment, product and geography FY2025 | TrendNalysis